keyword
MENU ▼
Read by QxMD icon Read
search

abatacept rheumatoid arthritis

keyword
https://www.readbyqxmd.com/read/29673963/no-difference-in-cardiovascular-risk-of-tocilizumab-versus-abatacept-for-rheumatoid-arthritis-a-multi-database-cohort-study
#1
Seoyoung C Kim, Daniel H Solomon, James R Rogers, Sara Gale, Micki Klearman, Khaled Sarsour, Sebastian Schneeweiss
OBJECTIVES: While tocilizumab may increase serum lipid levels, recent studies do not suggest a link between tocilizumab use and clinical cardiovascular risk in patients with rheumatoid arthritis (RA). METHODS: To compare cardiovascular safety of tocilizumab with abatacept, we conducted a cohort study using data from Medicare (2010-2013), IMS PharMetrics (2011-2014) and MarketScan (2011-6/2015). RA patients aged ≥18 years who newly started tocilizumab or abatacept entered the cohort on the day of their first use of tocilizumab or abatacept after a continuous enrollment period for ≥365 days...
March 22, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29657830/conversion-to-seronegative-status-after-abatacept-treatment-in-patients-with-early-and-poor-prognostic-rheumatoid-arthritis-is-associated-with-better-radiographic-outcomes-and-sustained-remission-post-hoc-analysis-of-the-agree-study
#2
Diahann T S L Jansen, Paul Emery, Josef S Smolen, Rene Westhovens, Manuela Le Bars, Sean E Connolly, June Ye, René E M Toes, Tom W J Huizinga
Objective: To evaluate the effects of the T-cell costimulation blocker abatacept on anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) in early rheumatoid arthritis (RA), and associations between changes in serological status and clinical response. Methods: Post hoc analysis of the phase III AGREE study in methotrexate (MTX)-naïve patients with early RA and poor prognostic factors. Patients were randomised to abatacept (~10 mg/kg intravenously according to weight range) or placebo, plus MTX over 12 months followed by open-label abatacept plus MTX for 12 months...
2018: RMD Open
https://www.readbyqxmd.com/read/29657147/longterm-safety-and-efficacy-of-subcutaneous-abatacept-in-patients-with-rheumatoid-arthritis-5-year-results-from-a-phase-iiib-trial
#3
Mark C Genovese, César Pacheco-Tena, Arturo Covarrubias, Gustavo Leon, Eduardo Mysler, Mauro Keiserman, Robert M Valente, Peter Nash, J Abraham Simon-Campos, Jane Box, Clarence W Legerton, Evgeny Nasonov, Patrick Durez, Ayanbola Elegbe, Robert Wong, Xiaohui Li, Subhashis Banerjee, Rieke Alten
OBJECTIVE: To assess 5-year safety, tolerability, and efficacy of subcutaneous (SC) abatacept (ABA) in methotrexate (MTX)-refractory patients with rheumatoid arthritis (RA). METHODS: The Abatacept Comparison of sub[QU]cutaneous versus intravenous in Inadequate Responders to methotrexatE (ACQUIRE) phase IIIb, randomized, double-dummy, multinational trial compared efficacy and safety of SC and intravenous (IV) ABA in patients with RA. In the initial 6-month double-blind (DB) period, patients received IV or SC ABA, plus MTX, and in the subsequent open-label longterm extension (LTE) period, all patients received SC ABA (125 mg/wk)...
April 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29652652/circulating-follicular-helper-t-cells-cd4-cxcr5-icos-decrease-in-patients-with-rheumatoid-arthritis-treated-with-abatacept
#4
Silvia Piantoni, Francesca Regola, Mirko Scarsi, Angela Tincani, Paolo Airò
No abstract text is available yet for this article.
April 13, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29651639/abatacept-for-treatment-of-rheumatoid-arthritis-special-focus-on-the-elderly
#5
Martin Soubrier, Clement Lahaye, Zuzana Tatar
Targeted therapies have been developed for patients with rheumatoid arthritis (RA) for whom prior treatment with traditional disease-modifying anti-rheumatic drugs has failed. The numerous different signaling pathways now targeted by various classes of monoclonal antibodies and small molecule inhibitors may complicate treatment decisions. Abatacept selectively modulates a co-stimulatory signal necessary for T-cell activation. Thus, abatacept is effective in biologic-naive patients and in those for whom biologic therapy has failed...
April 12, 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29614335/comparison-of-efficacy-of-tnf-inhibitors-and-abatacept-in-patients-with-rheumatoid-arthritis-adjusted-with-propensity-score-matching
#6
Satoshi Kubo, Shingo Nakayamada, Kazuhisa Nakano, Norifumi Sawamukai, Shintaro Hirata, Kentaro Hanami, Kazuyoshi Saito, Yoshiya Tanaka
The aim of this study was to compare the clinical outcome of patients with rheumatoid arthritis seen in routine clinical practice treated with either TNF inhibitors or abatacept. To overcome potential bias, both propensity score matching and Inverse Probability of Treatment Weighting were used for patient selection. The propensity score matching procedure selected 315 matched pairs of patients who were treated with TNF inhibitors or abatacept. At week 52, SDAI in TNF inhibitors was lower than abatacept. In contrast, analysis of biologics-naive patients using the propensity-score matching (n = 150; in each group) showed comparable clinical efficacy...
March 31, 2018: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/29600933/retention-and-clinical-response-to-abatacept-in-patients-with-rheumatoid-arthritis-an-italian-perspective
#7
Mauro Galeazzi, Rieke Alten, Melanie Chartier, Yedid Elbez, Enrico Fusaro, Manuela Le Bars, Hanns-Martin Lorenz, Giuseppa Pagano Mariano, Maurizio Muratore, Hubert G Nüßlein, Giovanni Patanè
No abstract text is available yet for this article.
March 21, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29600931/effects-of-biologic-disease-modifying-anti-rheumatic-drugs-on-the-radiographic-progression-of-rheumatoid-arthritis-a-systematic-literature-review
#8
REVIEW
Bernard Combe, Sadiq Lula, Caroline Boone, Patrick Durez
OBJECTIVES: To evaluate the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs) on radiographic progression in patients with rheumatoid arthritis (RA). METHODS: A systematic review of electronic databases and conference proceedings was conducted through January 2015, to identify randomised controlled trials (RCTs) and observational studies that assessed the impact of bDMARDs [± conventional synthetic DMARDs (csDMARDs), mainly methotrexate (MTX)], versus csDMARDs alone, on radiographic progression in patients with RA...
March 20, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29596207/use-of-abatacept-in-chilean-patients-with-long-standing-severe-rheumatoid-arthritis-without-previous-use-of-biologics
#9
Omar Valenzuela, Sebastián Ibáñez, María Paz Poblete, Claudia Mardones, Katherine Mogollones, Francisco Silva, María José Villar
No abstract text is available yet for this article.
March 29, 2018: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29592999/treatment-of-refractory-rheumatoid-pleural-effusion-with-abatacept
#10
Shunichi Fujita, Tomoyuki Mukai, Takahiko Akagi, Yoshitaka Morita
Rheumatoid pleural effusion is generally responsive to corticosteroids, but refractory cases require consideration of second-line therapy. Here we report the case of a 61-year-old man with rheumatoid arthritis (RA) who developed a large right-sided pleural effusion and was successfully treated with abatacept. Thoracocentesis showed a sterile exudate and an elevated adenosine deaminase level. The methotrexate and etanercept used to treat the RA were withheld initially while he underwent a trial of prednisolone 40 mg/day for the pleural effusion...
March 28, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29543846/drug-retention-and-discontinuation-reasons-between-seven-biologics-in-patients-with-rheumatoid-arthritis-the-answer-cohort-study
#11
Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Akira Ohnishi, Daijiro Kabata, Toru Hirano, Ryota Hara, Masaki Katayama, Shuzo Yoshida, Koji Nagai, Yonsu Son, Hideki Amuro, Kengo Akashi, Takanori Fujimura, Makoto Hirao, Keiichi Yamamoto, Ayumi Shintani, Atsushi Kumanogoh, Hideki Yoshikawa
The purpose of this study was to evaluate the retention and discontinuation reasons of seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of patients with rheumatoid arthritis (RA). 1,037 treatment courses with bDMARDs from 2009 to 2016 [female, 81.8%; baseline age, 59.6 y; disease duration 7.8 y; rheumatoid factor positivity 81.5%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR), 4.4; concomitant prednisolone 43.5% and methotrexate 68...
2018: PloS One
https://www.readbyqxmd.com/read/29535527/effects-of-denosumab-on-bone-metabolism-and-bone-mineral-density-with-anti-tnf-inhibitors-tocilizumab-or-abatacept-in-osteoporosis-with-rheumatoid-arthritis
#12
Takako Suzuki, Yukio Nakamura, Hiroyuki Kato
Introduction: The aim of this 18-month retrospective study was to evaluate the differences in outcomes of denosumab with tumor necrosis factor (TNF) inhibitors (TNFis), tocilizumab (TCZ), or abatacept (ABT) treatment in osteoporosis (OP) patients with rheumatoid arthritis (RA). Patients and methods: Patients were divided into TNFis-treated (TNF group; 44 cases), TCZ-treated (TCZ group; 8 cases), or ABT-treated (ABT group; 14 cases) groups. We measured serum bone-specific alkaline phosphatase (BAP) and tartrate-resistant acid phosphatase 5b (TRACP-5b) at baseline and every 3 months for 18 months and assessed bone mineral density (BMD) of the lumbar 1-4 vertebrae (L-BMD) and total hip BMD (H-BMD) at baseline and every 6 months for 18 months...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29532302/a-case-of-disseminated-histoplasmosis-in-a-patient-with-rheumatoid-arthritis-on-abatacept
#13
Nina Jain, Jeffrey B Doyon, Jacob E Lazarus, Inga-Marie Schaefer, Melanie E Johncilla, Agoston T Agoston, Anuj K Dalal, Gustavo E Velásquez
Biologic agents are effective treatments for rheumatoid arthritis but are associated with important risks, including severe infections. Tumor Necrosis Factor (TNF) α inhibitors are known to increase the risk of systemic fungal infections such as disseminated histoplasmosis. Abatacept is a biologic agent with a mechanism different from that of TNFα inhibitors: It suppresses cellular immunity by competing for the costimulatory signal on antigen-presenting cells. The risk of disseminated histoplasmosis for patients on abatacept is not known...
March 12, 2018: Journal of General Internal Medicine
https://www.readbyqxmd.com/read/29500936/ctla-4ig-abatacept-balances-bone-anabolic-effects-of-t-cells-and-wnt-10b-with-antianabolic-effects-of-osteoblastic-sclerostin
#14
Susanne Roser-Page, Tatyana Vikulina, Daiana Weiss, Mark M Habib, George R Beck, Roberto Pacifici, Timothy F Lane, M Neale Weitzmann
Activated lymphocytes promote inflammation and bone destruction in rheumatoid arthritis (RA), making T cells and B cells therapeutic targets. Indeed, pharmacological blockade of CD28 costimulation using CTLA-4Ig (abatacept), approved for amelioration of RA, renders T cells dormant (anergic). CTLA-4Ig also promotes bone accretion in healthy mice; surprisingly, however, this effect is driven exclusively through upregulation of bone formation, rather than anti-inflammatory effects on resorption. In the study presented here, we utilized T cell receptor β gene and Wnt-10b gene knockout mice to investigate the roles of T cells and Wnt-10b in CTLA-4Ig-induced bone anabolism...
March 3, 2018: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/29493381/comparing-the-effectiveness-of-biological-disease-modifying-antirheumatic-drugs-using-real-world-data
#15
Katsuhiko Takabayashi, Fumihiko Ando, Takahiro Suzuki
OBJECTIVES: To compare the effectiveness of biological disease-modifying antirheumatic drugs (bDMARDs) by analyzing claims data of 13 Japanese national university hospitals. METHODS: We evaluated 4,970 cases of rheumatoid arthritis treated with bDMARDs from the Clinical Information Statistical Analysis database, which has collected and integrated 13 Japanese national university hospitals' claims data for 10 years. We surveyed the medications and calculated the retention rates of bDMARDs using the Kaplan-Meier method and differentiated the effectiveness between the two bDMARDs by comparing the retention rates after switching from one drug to another...
March 1, 2018: Modern Rheumatology
https://www.readbyqxmd.com/read/29477401/cost-effectiveness-analysis-of-abatacept-compared-with-adalimumab-on-background-methotrexate-in-biologic-naive-adult-patients-with-rheumatoid-arthritis-and-poor-prognosis
#16
Evo Alemao, Sukhvinder Johal, Maiwenn J Al, Maureen Rutten-van Mölken
OBJECTIVES: To assess cost effectiveness of abatacept versus adalimumab, each administered with methotrexate, in treating patients with rheumatoid arthritis (RA) stratified according to baseline anticitrullinated protein antibody (ACPA) levels (marker of poor prognosis in RA). METHODS: A payer-perspective cost-effectiveness model simulated disease progression in patients with RA who had previously failed conventional disease-modifying antirheumatic drugs and were starting biologic therapy...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29445863/use-of-biological-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-in-austria-from-2008-to-2011-a-retrospective-analysis-of-72-of-the-population
#17
Tanja A Stamm, Berthold Reichardt, Jochen Zwerina, Valentin Ritschl, Valerie Nell-Duxneuner
BACKGROUND: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed in patients with RA. The aim of the present study was to explore prescription patterns of bDMARDs in RA in Austria with a focus on drug survival. METHODS: A retrospective data analysis of bDMARD courses of individual patients with RA that were extracted from the databases of nine Austrian health insurance funds covering 6...
February 14, 2018: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/29422324/abatacept-in-patients-with-rheumatoid-arthritis-and-interstitial-lung-disease-a-national-multicenter-study-of-63-patients
#18
Carlos Fernández-Díaz, Javier Loricera, Santos Castañeda, Raquel López-Mejías, Clara Ojeda-García, Alejandro Olivé, Samantha Rodríguez-Muguruza, Patricia E Carreira, Trinidad Pérez-Sandoval, Miriam Retuerto, Evelin C Cervantes-Pérez, Bryan J Flores-Robles, Blanca Hernández-Cruz, Ana Urruticoechea, Olga Maíz-Alonso, Luis Arboleya, Gema Bonilla, Íñigo Hernández-Rodríguez, Desirée Palma, Concepción Delgado, Rosa Expósito-Molinero, Ana Ruibal-Escribano, Belén Álvarez-Rodríguez, Juan Blanco-Madrigal, José A Bernal, Paloma Vela-Casasempere, Manuel Rodríguez-Gómez, Concepción Fito, Francisco Ortiz-Sanjuán, Javier Narváez, Manuel Moreno, Mireia López-Corbeto, Natalia Mena-Vázquez, Clara Aguilera-Cros, Susana Romero-Yuste, Sergi Ordóñez, Ignacio Villa-Blanco, M Carmen Gonzélez-Vela, Víctor Mora-Cuesta, Natalia Palmou-Fontana, José L Hernández, Miguel A González-Gay, Ricardo Blanco
OBJECTIVE: Interstitial lung disease (ILD) is one of the most serious complications of rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept (ABA) in patients with ILD associated to RA. METHODS: National multicenter, non-controlled, open-label registry study of RA patients with ILD treated with ABA. RESULTS: 63 patients (36 women) with RA-associated ILD undergoing ABA therapy were studied. The mean ± standard deviation age at the time of the study was 63...
January 6, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29401118/how-does-abatacept-really-work-in-rheumatoid-arthritis
#19
Michael Bonelli, Clemens Scheinecker
PURPOSE OF REVIEW: The purpose of this review is to summarize the current knowledge concerning the mechanisms of action of Abatacept in patients with rheumatoid arthritis. RECENT FINDINGS: Abatacept (CTLA-4Ig) represents a soluble, recombinant, fully humanized fusion protein, comprising the extracellular domain of CTLA-4 and the Fc portion of IgG1. Abatacept binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells (APC), thereby blocking interaction with CD28 on T cells...
May 2018: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/29367417/comparative-cardiovascular-risk-of-abatacept-and-tumor-necrosis-factor-inhibitors-in-patients-with-rheumatoid-arthritis-with-and-without-diabetes-mellitus-a-multidatabase-cohort-study
#20
Eun Ha Kang, Yinzhu Jin, Gregory Brill, Jennifer Lewey, Elisabetta Patorno, Rishi J Desai, Seoyoung C Kim
BACKGROUND: We examined the cardiovascular risk of abatacept compared with tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus (DM). METHODS AND RESULTS: We conducted a cohort study of patients with rheumatoid arthritis who newly started abatacept or TNF inhibitors using claims data from Medicare and MarketScan. The primary outcome was a composite cardiovascular end point of myocardial infarction (MI), stroke/transient ischemic attack, and coronary revascularization...
January 24, 2018: Journal of the American Heart Association
keyword
keyword
94163
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"